NAGE Niagen Bioscience, Inc.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1386570 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.9%
TTM net income YoY-49.9%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR13.6%
Net income 3-yr CAGR—
Margins
Gross margin63.9%
Operating margin3.9%
Net margin8.4%
FCF margin—
EBITDA margin4.3%
Returns
ROE13.3%
ROA9.9%
ROIC (approx.)44.3%
Asset turnover1.18x
Leverage & solvency
Liabilities / assets23.6%
Debt / equity0.00x
Current ratio5.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $129.42M | $99.60M |
| Cost of revenue | $46.23M | $38.01M |
| Gross profit | $83.19M | $61.59M |
| R&D expense | $6.33M | $6.02M |
| SG&A expense | $27.06M | $18.38M |
| Operating income | $16.28M | $7.73M |
| Pretax income | $18.19M | $8.86M |
| Income tax | $810,000 | $305,000 |
| Net income | $17.38M | $8.55M |
| EBITDA | $16.89M | $8.39M |
| EPS (basic) | 0.22 | 0.11 |
| EPS (diluted) | 0.20 | 0.11 |
| Weighted avg. shares (diluted) | 85.44M | 78.12M |
| Balance sheet | ||
| Cash & equivalents | $64.79M | $44.66M |
| Receivables | $9.74M | $7.77M |
| Inventory | $20.42M | $9.19M |
| Current assets | $96.81M | $64.10M |
| PP&E, net | $1.32M | $1.72M |
| Intangibles | $5.66M | $359,000 |
| Total assets | $106.41M | $68.28M |
| Current liabilities | $19.92M | $17.95M |
| Total liabilities | $29.87M | $22.18M |
| Shareholders' equity | $76.53M | $46.09M |
| Shares outstanding | 79.71M | 77.33M |
| Cash flow statement | ||
| Operating cash flow | $13.50M | $12.11M |
| Investing cash flow | -$292,000 | -$143,000 |
| Financing cash flow | $6.92M | $5.37M |
| Depreciation & amortization | $612,000 | $663,000 |
| Stock-based compensation | $6.07M | $3.66M |
| Share buybacks | $251,000 | $0 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.